Change Agents Raises $300,000 OID Note Financing and Issues 100,000 Pre-Funded Warrants

Change Agents raised $550,000 by issuing $616,000 in promissory notes due May 2027, using funds to refinance debt and improve liquidity. Notes carry 7% interest, with 15% upon default, and are prepayable at 105% of principal. The company also issued 1,000,000 pre-funded warrants at $0.0001 to support the financing, according to the company.

General Dynamics plans to expand its Quebec facility, producing M31A2 propellant for 155mm artillery shells, with $390M from the U.S. and $1.1B from Canada. The BAPE urged Quebec to consider potential international humanitarian law violations. The propellant is exported to the U.S. and used in Israel's military operations, raising concerns about civilian harm and human rights.

SITE Centers Corp. (SITC) stock rose 14.95% following announcements of asset sales and a $3.00 per-share special cash dividend. The company reported revenue of $10.7M, EBITDA of $2.7M, and a net loss of $7.4M for the recent quarter, but highlighted strong liquidity and no long-term debt. Analysts note positive risk/reward, with key support at $3.00 and resistance at $3.75.

Michael Saylor, Strategy's executive chairman, revealed that credit investors prefer cash over Bitcoin as collateral. Strategy's 12% yield preferred stock (STRC) fell below $100, prompting a $1.5 billion share buyback and a cash dividend reserve. Saylor now advocates for a mix of Bitcoin and cash for digital credit, with Strategy holding 3.5 years of dividends in cash. STRC trades near par, and Saylor expects it to tighten 200-300 basis points.

Vaxcyte's stock fell 2.53% after a $1.15 billion capital raise, causing investor concerns about dilution. The company plans to use the funds for Phase 3 trials of its VAX-31 vaccine, expected to report data by October 2026. Vaxcyte remains pre-revenue with widening losses, raising questions about long-term financial flexibility.

HDFC Bank deputy MD Kaizad Bharucha plans to leave by Dec 2026, pending RBI approval. The board approved Lily Vadera's reappointment as independent director for 3 years, subject to shareholder approval. Bharucha's departure follows a 30-year tenure, while Vadera brings extensive central banking experience.